Final results of a phase II multicenter trial of HF10, a replication-competent HSV-1 oncolytic virus, and ipilimumab combination treatment in patients with stage IIIB-IV unresectable or metastatic melanoma.

医学 内科学 临床终点 易普利姆玛 肿瘤科 癌症 胃肠病学 临床试验 免疫疗法
作者
Robert Hans Ingemar Andtbacka,Merrick I. Ross,Sanjiv S. Agarwala,Matthew H. Taylor,John T. Vetto,Rogerio I. Neves,Adil Daud,Hung T. Khong,Richard S. Ungerleider,Maki Tanaka,Kenneth F. Grossmann
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:35 (15_suppl): 9510-9510 被引量:47
标识
DOI:10.1200/jco.2017.35.15_suppl.9510
摘要

9510 Background: HF10 is a bioselected replication-competent oncolytic virus derived from HSV-1. Herein, we report the safety and efficacy data of HF10 + ipilimumab (ipi) combination treatment in a Phase II trial in melanoma. Methods: Key entry criteria: age ≥ 18 yrs, ECOG ≤ 2, Stage IIIB, IIIC, or IV unresectable melanoma, ipi naïve (IV administration) and measurable non-visceral lesion(s) suitable for injection. HF10 injected into single or multiple tumors (1 x 10 7 TCID 50 /mL/dose, up to 5mL depending on tumor size and number); 4 injections q1wk; then up to 15 injections q3wk. Four ipi IV infusions (3 mg/kg; concurrent with HF10) were administered q3wk. AEs assessed per CTCAE 4.0. Tumor responses were assessed per mWHO and irRC at 12, 18, 24, 36 and 48 wks for patients (pts) continuing on HF10 monotherapy. Primary endpoint was Best Overall Response Rate (BORR) at 24 wks. Dose limiting toxicity (DLT) defined as ≥ G3 non-hematologic/hematologic toxicity, ≥ G2 neurologic toxicity, or allergic event occurring within 1 st 3wks of therapy. Results: Of 46 pts enrolled and treated: 59% men, median age 67 yrs (range 28 to 91); disease stage 20% IIIB, 43% IIIC and 37% IV; 57% were treatment naïve and 43% with ≥ 1 prior cancer therapy for unresectable/metastatic melanoma. Most HF10-related AEs were ≤G2, similar to HF10 monotherapy. No DLTs were reported. 37% had ≥G3 AEs, the majority due to ipi. HF10-related ≥G3 AEs (n=3) were embolism, lymphedema, diarrhea, hypoglycemia, and groin pain. Of the 44 efficacy evaluable pts per irRC, BORR at 24 weeks was 41% (16% irCR and 25% irPR); disease stability rate was 68% (16% irCR, 25% irPR and 27% irSD). As of Feb 06, 2017, median PFS was 19 months and median overall survival was 21.8 months. Conclusions: The combination HF10 and ipilimumab treatment demonstrated a favorable benefit/risk profile and encouraging antitumor activity in pts with stage IIIB, IIIC, or IV unresectable or metastatic melanoma. Clinical trial information: NCT02272855.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
大橙子发布了新的文献求助10
2秒前
4秒前
Zhh完成签到 ,获得积分10
4秒前
Tina完成签到,获得积分10
6秒前
微生完成签到 ,获得积分10
6秒前
7秒前
chhzz完成签到 ,获得积分10
8秒前
飞舞伤寒发布了新的文献求助20
8秒前
曾珍发布了新的文献求助10
10秒前
qwe完成签到,获得积分10
11秒前
Xdz完成签到 ,获得积分10
11秒前
cai完成签到 ,获得积分10
14秒前
雨恋凡尘完成签到,获得积分0
17秒前
羊羔肉完成签到,获得积分10
19秒前
胖丁完成签到,获得积分10
19秒前
笨笨凡松完成签到,获得积分10
22秒前
飞舞伤寒完成签到,获得积分10
22秒前
贝利亚完成签到,获得积分10
24秒前
喜多多的小眼静完成签到 ,获得积分10
24秒前
24秒前
Dsunflower完成签到 ,获得积分10
25秒前
羊羔肉发布了新的文献求助50
26秒前
半夏发布了新的文献求助10
26秒前
27秒前
27秒前
大橙子发布了新的文献求助10
28秒前
星辰大海应助贝利亚采纳,获得10
28秒前
29秒前
sunny心晴完成签到 ,获得积分10
31秒前
独特的凝云完成签到 ,获得积分10
31秒前
TheDing完成签到,获得积分10
32秒前
传奇3应助lenetivy采纳,获得10
34秒前
积极的忆曼完成签到,获得积分10
35秒前
量子星尘发布了新的文献求助10
35秒前
酒剑仙完成签到,获得积分10
35秒前
YANGMJ完成签到,获得积分10
36秒前
xialuoke完成签到,获得积分10
36秒前
scinature发布了新的文献求助10
37秒前
37秒前
37秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038201
求助须知:如何正确求助?哪些是违规求助? 3575940
关于积分的说明 11373987
捐赠科研通 3305747
什么是DOI,文献DOI怎么找? 1819274
邀请新用户注册赠送积分活动 892662
科研通“疑难数据库(出版商)”最低求助积分说明 815022